121 related articles for article (PubMed ID: 9124852)
1. Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults.
Riddler SA; Wang LH; Bartlett JA; Savina PM; Packard MV; McMahon DK; Blum MR; Dunn JA; Elkins MM; Mellors JW
Antimicrob Agents Chemother; 1996 Dec; 40(12):2842-7. PubMed ID: 9124852
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
[TBL] [Abstract][Full Text] [Related]
3. 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.
Daluge SM; Purifoy DJ; Savina PM; St Clair MH; Parry NR; Dev IK; Novak P; Ayers KM; Reardon JE; Roberts GB
Antimicrob Agents Chemother; 1994 Jul; 38(7):1590-603. PubMed ID: 7526782
[TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
Wang LH; Chittick GE; McDowell JA
Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227
[TBL] [Abstract][Full Text] [Related]
5. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.
Sadler BM; Hanson CD; Chittick GE; Symonds WT; Roskell NS
Antimicrob Agents Chemother; 1999 Jul; 43(7):1686-92. PubMed ID: 10390223
[TBL] [Abstract][Full Text] [Related]
7. Validation of a high-performance liquid chromatographic-mass spectrometric method for the measurement of 5-chloro-2',3'-dideoxy-3' -fluorouridine (935U83) in human plasma.
Dunn JA; Savina PM
J Chromatogr B Biomed Appl; 1996 Nov; 686(2):241-8. PubMed ID: 8971606
[TBL] [Abstract][Full Text] [Related]
8. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects.
Wang LH; Peck RW; Yin Y; Allanson J; Wiggs R; Wire MB
Antimicrob Agents Chemother; 2003 Apr; 47(4):1334-42. PubMed ID: 12654667
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.
Jacobson MA; Gallant J; Wang LH; Coakley D; Weller S; Gary D; Squires L; Smiley ML; Blum MR; Feinberg J
Antimicrob Agents Chemother; 1994 Jul; 38(7):1534-40. PubMed ID: 7979285
[TBL] [Abstract][Full Text] [Related]
10. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers.
Zhao N; Xie R; Zhao X; Zhao H; Jia B; Zhang Y; Luo L; Huang Z; Li J; Wang X; Yan H; He B; Xie H; Ren Q; Cui Y
Clin Drug Investig; 2019 Jul; 39(7):671-681. PubMed ID: 31079356
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.
Mallalieu NL; Rahimy MH; Crowley CA; Appleman JR; Smith PF; Freddo JL
Clin Ther; 2014 Dec; 36(12):2047-2063.e3. PubMed ID: 25456558
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
17. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food.
Chittick GE; Gillotin C; McDowell JA; Lou Y; Edwards KD; Prince WT; Stein DS
Pharmacotherapy; 1999 Aug; 19(8):932-42. PubMed ID: 10453964
[TBL] [Abstract][Full Text] [Related]
18. Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects.
Scherrer D; Rouzier R; Cardona M; Barrett PN; Steens JM; Gineste P; Murphy RL; Tazi J; Ehrlich HJ
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799203
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.
McDowell JA; Chittick GE; Ravitch JR; Polk RE; Kerkering TM; Stein DS
Antimicrob Agents Chemother; 1999 Dec; 43(12):2855-61. PubMed ID: 10582871
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
